Sermorelin
Also known as: Sermorelin Acetate, GHRH(1–29)-amide, Geref, Sermorelin acetate
Sermorelin is the active GHRH (1–29) fragment with a historical Geref diagnostic and pediatric-treatment record. Adult hormone responses and selected functional findings do not establish broad anti-aging, fat-loss or muscle-mass benefits.
Quick Facts
Identity, mechanism and pharmacokinetics
Sermorelin is synthetic GHRH (1–29)-amide, the shortest fully active portion of the hypothalamic signal that stimulates anterior-pituitary GH secretion. It requires a responsive pituitary, unlike exogenous HGH, which supplies the hormone directly. Endogenous feedback through somatostatin can reduce the signal, but no head-to-head trial establishes a general safety advantage over HGH.
GH stimulates hepatic IGF-1 production. Sermorelin is shorter-acting than CJC-1295 but uses the same GHRH pathway. A ten-man IV study measured a 4.3-minute disappearance half-time; its D-Ala2 comparator was not CJC-1295. That IV result is not a subcutaneous administration interval.
Geref history, compounding and sport
Geref received diagnostic approval in 1990 and pediatric idiopathic-GH-deficiency treatment approval in 1997. The manufacturer discontinued it in 2008; specific approvals were withdrawn in 2009. FDA’s later determination found the products had not been withdrawn for safety or effectiveness reasons. That is a historical product finding, not current approval for adult anti-aging or performance use.
No current FDA-approved marketed sermorelin product or current DailyMed label is identified. Compounded supply has a different footing from never-approved ingredients, while its regulatory position remains under FDA review. GHRH analogs including sermorelin are prohibited at all times by WADA.
Direct adult research and regimen limits
GHRH physiology studies report augmented nocturnal GH release. This hormone-level finding does not establish improved muscle, fat, recovery or aging outcomes from sermorelin in healthy adults.
A six-week study in 11 older men reported greater nocturnal GH and selected strength/endurance improvements, without changes in IGF-I or DEXA muscle/fat measurements. A 14-day study in ten older men found dose-related GH and IGF-I responses, particularly at the higher exposure. These findings are biological/functional observations, not an established 2–3 kg muscle gain or general fat-loss effect.
The six-week study used 2 mg GHRH (1–29) nightly; the 14-day study tested 0.5 mg and 1 mg twice daily. These are research exposures rather than a universal 0.2–0.3 mg bedtime dose, workout schedule or cycle. Injectable study results do not validate an oral tablet, nasal spray or another formulation.
The small six-week study reported no significant adverse effects, but cannot measure rare risks, years of safety or comparative superiority. The acute GHRH/GHRP-6 combination study provides a mechanistic research rationale, not clinical proof for sermorelin/ipamorelin or a protective receptor-reset calendar.
GHRH-class findings are not sermorelin efficacy trials
Tesamorelin shares the GHRH receptor but has its own evidence base:
| Tesamorelin evidence | Reported result |
|---|---|
| 412-person HIV trial; 2 mg SC daily | At 26 weeks, VAT −15.2% versus +5.0% placebo; p < 0.001. |
| Pooled Phase III trials; 806 participants | Approximately 15.4% VAT treatment effect at 26 weeks, sustained through 52 weeks; no clinically meaningful mean glucose difference. |
| 12-month trial; 60 abdominally obese adults with reduced GH | Net 19% VAT reduction and 37 mg/dL triglyceride reduction versus placebo. |
| Secondary analysis; 341 adults with HIV; 26 weeks | In responders versus placebo, truncal muscle density +1.56–4.86 Hounsfield units (all p < 0.005), lean muscle area +0.64–1.08 cm² across four groups. |
| Meta-analysis of five HIV RCTs | Lean body mass mean increase 1.42 kg; 95% CI 1.13–1.71, p< 0.001. |
Those visceral-fat and lean-mass findings concern tesamorelin, not demonstrations that sermorelin improves muscle or fat in healthy adults. Selected functional changes in small sermorelin studies are a separate endpoint.
IGF-1, sleep and aging physiology
In seven men aged 65–78, a blunted GH response to testing improved after 100 micrograms IV GHRH-40 every two days for 12 days. A retrospective combination report in 14 men receiving testosterone plus sermorelin/GHRP-2/GHRP-6 for a mean 134 days found IGF-1 rose from 159.5 to 239.0 ng/mL, approximately 50% (p< 0.0001). Neither design isolates routine sermorelin wellness benefit.
IV GHRH sleep experiments found slow-wave sleep rose from 14.0% to 20.2% of total sleep time in seven healthy men—a 44% relative increase—and another young-men experiment reported almost a tenfold late-sleep increase. In older adults (mean age 69.3), awakenings decreased, but sleep/cortisol effects were smaller than in younger participants. Direct randomized subcutaneous-sermorelin sleep trials are not described.
“Somatopause” describes declining GH secretion beginning in early adulthood. Studies suggest contributions from reduced hypothalamic GHRH output and reduced pituitary responsiveness: some observed similar injected-GHRH responses by age, while others found a reduced response partly restored by repeated GHRH. These mechanisms do not establish longer life, fracture prevention, rejuvenated skin or a standard sleep/weight-results timetable.
References and further reading
This reference draws on Superpower’s Peptide Library and the research linked below. Peptide Dossier’s editorial team adapted and integrated the material on .
- 10.1530/eje.0.1510561Direct adult research and regimen limitsCited in: Direct adult research and regimen limits
- pubmed.ncbi.nlm.nih.govIdentity, mechanism and pharmacokineticsCited in: Identity, mechanism and pharmacokinetics
- pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
- pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
- pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
- pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
- pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
- pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
- pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
- pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
- federalregister.govGeref history, compounding and sportCited in: Geref history, compounding and sport
- pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
- pubmed.ncbi.nlm.nih.govGHRH-class findings are not sermorelin efficacy trialsCited in: GHRH-class findings are not sermorelin efficacy trials
- pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
- pubmed.ncbi.nlm.nih.govIGF-1, sleep and aging physiologyCited in: IGF-1, sleep and aging physiology
- www.govinfo.gov — additional readingGeref history, compounding and sportCited in: Geref history, compounding and sport
- pubmed.ncbi.nlm.nih.gov — additional readingDirect adult research and regimen limitsCited in: Direct adult research and regimen limits
- pubmed.ncbi.nlm.nih.gov — additional readingDirect adult research and regimen limitsCited in: Direct adult research and regimen limits
- pubmed.ncbi.nlm.nih.gov — additional readingIdentity, mechanism and pharmacokineticsCited in: Identity, mechanism and pharmacokinetics
- pubmed.ncbi.nlm.nih.gov — additional readingDirect adult research and regimen limitsCited in: Direct adult research and regimen limits
Frequently Asked Questions About Sermorelin
Sermorelin stimulates the GHRH pathway; exogenous GH provides the hormone directly. This mechanism does not establish a general safety advantage.
The six-week older-men study found selected strength changes but no DEXA muscle or fat change. It does not establish a standard before-and-after timeline.
The small six-week study reported no significant adverse effects, but it cannot establish uncommon risks, long-term safety or comparative superiority.
Different studies used different research exposures. They do not establish a universal 0.2–0.3 mg dose, bedtime schedule or protective cycle.
Tesamorelin has specific current EGRIFTA labeling for HIV-associated lipodystrophy; Geref has a separate historical record. This is not a head-to-head efficacy or safety comparison.
The cited studies do not establish a general weight-loss indication or a standard amount of fat loss.
Historical Geref products and the cited research used injections. Their findings cannot verify the identity, availability or efficacy of a particular oral or nasal product.
Hormone responses and clinical changes are different endpoints. The studies do not establish a universal results calendar.
The 29-amino-acid GHRH analog stimulates a responsive pituitary; HGH supplies hormone directly. Feedback remains possible, but no head-to-head safety trial establishes a general advantage.
No. The strong visceral-fat studies summarized here used tesamorelin. Their receptor relationship does not make them sermorelin trials.
GH-axis stimulation can increase IGF-1. Small physiology studies and a 14-man testosterone/sermorelin/GHRP combination report support that biological activity, but do not isolate predictable wellness outcomes from sermorelin alone.
IV GHRH experiments found slow-wave-sleep changes, including 14.0% to 20.2% in seven men and smaller effects in older adults. These were not direct randomized subcutaneous-sermorelin sleep trials.
No marketed approved product is identified. Historical Geref diagnostic and pediatric approvals were discontinued; FDA later found withdrawal was not for safety or effectiveness. Compounding status remains a separate question.
A small sermorelin study found selected strength/endurance changes without DEXA muscle/fat change. The stronger lean-mass and muscle-area estimates discussed here come from tesamorelin, not sermorelin.
It is the age-related decline in GH secretion, with evidence implicating both less hypothalamic signaling and a less responsive pituitary. Some responsiveness can change with repeated GHRH; that does not establish anti-aging treatment benefit.
No universal home dose, bedtime rule, cycle or visible-results timetable is established by the differing small research regimens. The studies do not validate tablets or sprays.
No. Absence of significant adverse effects in a small six-week study cannot exclude rare risks, establish chronic safety or prove superiority to HGH.
Related Peptides
Continue exploring Sermorelin
- CJC-1295 vs Sermorelin: Identity, Human Evidence & Safety [2026]Comparison
- Ipamorelin vs Sermorelin: Growth Hormone Secretagogues Comparison 2026Comparison
- Sermorelin Before and After: Timeline of Results [2026]Guide
- Sermorelin Dosage Guide: Protocols and Administration [2026]Guide
- Sermorelin vs CJC-1295: Human Evidence and Key Differences [2026]Comparison
- Sermorelin vs GHRP-6: Human Research, Sleep and GH ResponseComparison
- Sermorelin vs Ipamorelin: Growth Hormone Peptide Comparison [2026]Guide
- Sermorelin vs Tesamorelin: Uses, Evidence & Formulations [2026]Comparison
Our library review is ongoing. Read how we evaluate evidence or report a correction.
Disclaimer: This article is for informational and educational purposes only. It is not intended as medical advice. The information presented is based on published research and should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting any peptide protocol. Some peptides discussed may not be approved for human use by the FDA or equivalent regulatory bodies.